Antimicrobial drug development
Antimicrobial drug development
Bacterial keratitis is an aggressive and devastating ocular disease that requires immediate, broad-spectrum antimicrobial treatment to mitigate tissue damage and maintain sight. However, rising antibiotic resistance, particularly among Staphylococcus aureus isolates has rendered many current ophthalmic antibiotic ineffective. Our lab is working to develop the next generation of ocular antibiotics to fill this critical need. We are actively exploring novel, synergistic drug combinations as well identifying new antimicrobial classes using high-throughput screening methodologies.